As shown previously in Figure 2, increased expression of ERO1α is a poor prognostic indicator in lung adenocarcinoma, hepatocellular carcinoma, esophageal carcinoma, and diffuse B-cell lymphoma; However, ERO1α has also be found to be a poor prognostic indicator in breast cancer by multiple researchers [37,38]. This evidence concerns the gene ERO1A and hepatocellular carcinoma.